Key points are not available for this paper at this time.
Treatment with IDegLira over 18 months resulted in greater HbA1c reductions, weight loss versus gain, and a lower rate of hypoglycaemia versus ICT in people with type 2 diabetes.
Szépkúti et al. (Wed,) studied this question.